Expert NetworkExpert InterviewALLO

Slingshot members are talking to an expert! The topic is:

Discussing Allogene Therapeutics' Cemacabtagene Ansegedleucel (Cema-Cel), an Allogeneic Anti-CD19 CAR-T Therapy for First-Line Consolidation in Large B-Cell Lymphoma

Executed on:Apr 29, 2026 11:00 AM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: Duke University Medical Center
  • Chief, Division of Cell Therapy in the Department of Medicine
  • Manages 30 patients with large B-cell lymphoma
  • Research interests are in two broad areas, clinical hematopoietic stem cell and cord blood transplantation and in the laboratory studies related to graft vs. host disease and immune reconstitution

Interview Goal

To gain a deeper understanding of Cemacabtagene Ansegedleucel (Cema-Cel), an Allogeneic Anti-CD19 CAR-T Therapy for First-Line Consolidation in Large B-Cell Lymphoma

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.